Share Taofeek K. Owonikoko, MD, PhD, MS / Ticiana Leal, MD - New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3–Directed ADCs

Copy link

December 12, 2025

Taofeek K. Owonikoko, MD, PhD, MS / Ticiana Leal, MD - New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3–Directed ADCs

1 hour 1 minute

Please visit answersincme.com/860/99097105-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in small cell lung cancer (SCLC) discuss the pathophysiologic rationale, emerging clinical evidence, and potential future role for B7-H3–directed antibody-drug conjugates in extensive-stage SCLC. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating B7-H3–directed antibody-drug conjugates (ADCs) in the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC); Analyze recent clinical trial findings on B7-H3–directed ADCs in patients with previously treated ES-SCLC; and Formulate evidence-based, multidisciplinary team strategies for incorporating B7-H3–directed ADCs into treatment plans for patients with ES-SCLC, as they become available.

...more